


## Antimicrobial agent-5

Cat. No.:	HY-151399
Molecular Formula:	C <sub>32</sub> H <sub>48</sub> N <sub>16</sub>
Molecular Weight:	656.83
Target:	Bacterial
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Antimicrobial agent-5 is a potent antimicrobial agent, and displays excellent cell selectivity against Gram-negative bacteria and Gram-positive bacteria. Antimicrobial agent-5 blocks the interaction between LPS and CD14/TLR4 receptor, and shows anti-inflammatory activity against LPS-induced inflammation <sup>[1]</sup> .																
<b>In Vitro</b>	<p>Antimicrobial agent-5 (compound 9) (0.5-32 µg/mL, 16 h; 1-128 µg/mL; 24 h) shows potent biofilm inhibitory (IC<sub>50</sub>=2 µg/mL) and eradicating activities (IC<sub>50</sub>=16 µg/mL) against multidrug-resistant <i>Pseudomonas aeruginosa</i> (MDRPA)<sup>[1]</sup>.</p> <p>Antimicrobial agent-5 (5 µg/mL, 20 µg/mL; 18 h) inhibits both the release and expression of nitric oxide (NO) and tumor necrosis factor-α (TNF-α) from LPS-stimulated (1 µg/mL) RAW 264.7 cells<sup>[1]</sup>.</p> <p>Antimicrobial agent-5 exhibits proteolytic resistance and salt/serum stability<sup>[1]</sup>.</p> <p>Antimicrobial agent-5 (0.5-256 µg/mL; 2 h) exhibits negligible side effects against sheep red blood cells (sRBCs) with hemolytic activity (the minimum hemolytic concentration, MHC) of &gt;256 µg/mL<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>RAW264.7 cells</td> </tr> <tr> <td>Concentration:</td> <td>5 µg/mL, 20 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>18 hours</td> </tr> <tr> <td>Result:</td> <td>Decreased TNF-α release at 20 µg/mL, with inhibition rate of 72.44%. Results reduction in the LPS-stimulated production of NO, with inhibition rate of 31.51%.</td> </tr> </table> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td><i>E. coli</i> [KCTC 1682], <i>P. aeruginosa</i> [KCTC 1637], <i>S. epidermidis</i> [KCTC 1917], <i>S. aureus</i> [KCTC1621]</td> </tr> <tr> <td>Concentration:</td> <td>1-128 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited Gram-negative bacteria and Gram-positive bacteria with IC<sub>50</sub> of 6.1 µM (<i>E. coli</i> [KCTC 1682], <i>P. aeruginosa</i> [KCTC 1637], <i>S. epidermidis</i> [KCTC 1917], <i>S. aureus</i> [KCTC1621]), respectively.</td> </tr> </table>	Cell Line:	RAW264.7 cells	Concentration:	5 µg/mL, 20 µg/mL	Incubation Time:	18 hours	Result:	Decreased TNF-α release at 20 µg/mL, with inhibition rate of 72.44%. Results reduction in the LPS-stimulated production of NO, with inhibition rate of 31.51%.	Cell Line:	<i>E. coli</i> [KCTC 1682], <i>P. aeruginosa</i> [KCTC 1637], <i>S. epidermidis</i> [KCTC 1917], <i>S. aureus</i> [KCTC1621]	Concentration:	1-128 µg/mL	Incubation Time:	24 hours	Result:	Inhibited Gram-negative bacteria and Gram-positive bacteria with IC <sub>50</sub> of 6.1 µM ( <i>E. coli</i> [KCTC 1682], <i>P. aeruginosa</i> [KCTC 1637], <i>S. epidermidis</i> [KCTC 1917], <i>S. aureus</i> [KCTC1621]), respectively.
Cell Line:	RAW264.7 cells																
Concentration:	5 µg/mL, 20 µg/mL																
Incubation Time:	18 hours																
Result:	Decreased TNF-α release at 20 µg/mL, with inhibition rate of 72.44%. Results reduction in the LPS-stimulated production of NO, with inhibition rate of 31.51%.																
Cell Line:	<i>E. coli</i> [KCTC 1682], <i>P. aeruginosa</i> [KCTC 1637], <i>S. epidermidis</i> [KCTC 1917], <i>S. aureus</i> [KCTC1621]																
Concentration:	1-128 µg/mL																
Incubation Time:	24 hours																
Result:	Inhibited Gram-negative bacteria and Gram-positive bacteria with IC <sub>50</sub> of 6.1 µM ( <i>E. coli</i> [KCTC 1682], <i>P. aeruginosa</i> [KCTC 1637], <i>S. epidermidis</i> [KCTC 1917], <i>S. aureus</i> [KCTC1621]), respectively.																

---

## REFERENCES

---

[1]. Dinesh Kumar S, et al. Cationic, amphipathic small molecules based on a triazine-piperazine-triazine scaffold as a new class of antimicrobial agents. Eur J Med Chem. 2022 Sep 8;243:114747.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA